Macrocyclic Peptides Are Expanding Drug Discovery
Macrocyclic peptides blend antibody-like specificity with small-molecule manufacturability, unlocking undruggable PPI targets, stability, and oral potential.
Methods used to find and design new peptide drugs, including display technologies, macrocycles, multi-agonist design, peptide-drug conjugates and computational approaches. Articles describe the techniques and their documented limitations rather than forecasting outcomes.
5 articles by Brian Gossett. Read our editorial standards.
Macrocyclic peptides blend antibody-like specificity with small-molecule manufacturability, unlocking undruggable PPI targets, stability, and oral potential.
Peptide-drug conjugates (PDCs) pair a targeting peptide with a cytotoxic payload. See how PDCs compare to antibody-drug conjugates and who builds pipelines.
How AI is transforming peptide discovery: AlphaFold, generative design, machine-learning optimization, AI-designed antimicrobial peptides, faster timelines.
A complete guide to how new peptides are discovered: hormone isolation, venoms, rational design, phage and mRNA display, DNA-encoded libraries, AI, and SPPS.
How one peptide can activate several receptors at once: unimolecular co-agonism, GLP-1/GIP duals, GLP-1/glucagon, triple agonists, amylin combos, and design challenges.